Объявления
ABSCH Q&A Webinar on Community Protocols and Customary Laws Recording Available Now!
Every month the ABS Clearing-House Team hosts a question and answer webinar on a different topic. Th
ABSCH Q&A Webinar on Community Protocols and Customary Laws
24 May 2023 - 09:00 a.m. to 10:00 a.m EST
Сторона Nagoya Protocol
Национальные записи
Recently published
En esta investigación se pretende hacer un acercamiento al posible origen de los magueyes hispaniolanos, su relación con los magueyes continentales mexicanos y esclarecer el escenario molecular de la cantidad de especies para la hispaniola, con el objetivo de reconstruir la filogenia de los magueyes hispaniolanos usando como marcadores moleculares al gen Mayahuelina y otros genes de la familia de las RIPs (Proteínas inactivadoras de los ribosomas); Establecer el parentesco entre los magueyes hispanos y de América continental a nivel molecular; Explicar el origen y tiempo de diversificación de los magueyes de la Hispaniola a partir de sus ancestros mexicanos, centroamericanos y del Norte de Sudamérica más reciente y luego elaborar las claves de identificación para los magueyes de la Hispaniola.
Справочные записи
Recently published
In 1993, the Australian State of Queensland's Griffith University formed a partnership with Astra Pharmaecuticals to pursue a natural product (NP) drug discovery programme under the banner of the Queensland Pharmaceutical Research Institute (QPRI). This partnership persisted through the merger of Astra Pharmaceuticals with Zeneca to form AstraZeneca AB in 1999. QPRI was renamed AstraZeneca R&D Brisbane, then evolved into the Natural Product Discovery Unit (NPD), and finally moved under the aegis of the Eskitis Institute for Cell and Molecular Therapies
Contents 1. CABI’s ABS Policy and Best Practices 1 1.1 How CABI uses genetic material 1 1.2 Benefits CABI provides from its use of genetic material 2 2. Swiss legislation in relation to Access and Benefit Sharing (ABS) 2 3. CABI’s Best Practices and implementation in Switzerland 2 3.1 Accessing genetic resources for use (in situ) 3 3.2 Receiving biological and genetic resources from collaborators, collections or other providers (ex situ) 5 3.3 Transferring genetic material and/or resources outside of CABI 5 3.4 Enforcement and compliance 5 Annex 1: A glossary of useful terms and their definitions 6 Annex 2. Decision tree outlining the general steps of the CABI best practice. 8 Annex 3. CABI genetic resources database with an example entry 9 Annex 4. CABI generic MTA for supply of genetic resources 10
New updated edition of this comprehensive global survey of national ABS regulations, highlights the continuous progress in the establishment and implementation of national ABS regulations around the world.
This document has been produced in order to provide assurance to Nagoya Protocol member states, regulators, researchers, collaborators and peers, that the Wellcome Sanger Institute has initiated and carries out appropriate processes and procedures to enable compliance with global Access and Benefit Sharing (hereafter; ABS) measures and compliance with the UK ABS legislation5 implementing the Nagoya Protocol1 for scientific research undertaken. Within this document are the tools, processes and procedures, comprising Institute policy, that when employed correctly staff and associates of the Wellcome Sanger Institute can be confident that they are conducting their research in accordance with the UK ABS legislation and in turn, ABS legislation in force globally.
